CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice

AIM To apply extended ctDNA-based RAS genotyping to clinical criteria for improving the selection of patients eligible for anti-EGFR-based rechallenge in a real-world setting. METHODS ctDNA testing was prospectively applied to RASwt mCRC progressed after a first-line anti-EGFR-containing regimen and at least one other line. The primary endpoint was the objective response rate. RESULTS Among ten enrolled patients, the anti-EGFR rechallenge resulted in an objective response rate and disease control rate of 70% and 90%. The median progression-free survival was 11.3 months and overall survival was not reached. Compared with a historical cohort retreated with anti-EGFR agents based on clinical criteria, the ctDNA-driven approach resulted in a higher chance of achieving an objective response and longer survival. CONCLUSIONS Blood-based RASwt status may enrich metastatic colorectal cancer more likely to benefit from anti-EGFR-based rechallenge. RAS genotyping in ctDNA represents a feasible, fast, and cost-effective tool to be implemented in the clinic for advancing precision medicine.

[1]  F. Perrone,et al.  Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. , 2021, Clinical colorectal cancer.

[2]  R. Labianca,et al.  Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. Bardelli,et al.  Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. , 2019, Cancer treatment reviews.

[4]  S. Kopetz,et al.  Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Danesi,et al.  Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial , 2019, JAMA oncology.

[6]  A. Bardelli,et al.  Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  N. Normanno,et al.  RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  J. Pignon,et al.  Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  V. Heinemann,et al.  The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. , 2017, European journal of cancer.

[10]  A. Bardelli,et al.  Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer , 2016, Nature Communications.

[11]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  F. Nicolantonio,et al.  Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.

[13]  P. Angenendt,et al.  Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  A. Russo,et al.  Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Peeters,et al.  Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice. , 2012, Cancer treatment reviews.

[16]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[17]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.